Global HCQ/CQ studies

November 15, 2020 @CovidAnalysis

Early treatment 100% of studies report p 64% is the median impro		171 HCQ studies 107 peer reviewed
Late	26%	Early treatment shows high efficacy
treatment	↓26%	Shows high enicacy

65% of studies report positive effects.

11/14	Meta	Early, <i>Covid Analysis (Preprint) (met</i> HCQ is effective for COVID-19 wh HCQ is effective for COVID-19. The probability that an ineffective treatment gen
11/13	Positive	Late Sheshah et death, ↓80.0 Prevalence of Diabetes, Manage Retrospective 300 hospitalized patients in Saudi Arabia showing HCQ adjusted
11/12	Positive	Early Simova et al hosp., ↓96.7 Hydroxychloroquine for prophylax 100% reduction in hospitalization and cases with early treatment using HCQ+AZ
11/12	Positive	 PEP Simova et al cases, ↓95 Hydroxychloroquine for prophylax 100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report
11/12	Meta	N/A Tchounga et al., Journal of Pha Composition analysis of falsified Analysis of fake CQ tablets finding: - no CQ in six samples, substituted with met
11/11	Positive	LateÁguila-Gorddeath, ↓67.0Mortality and associated prognos67% lower mortality with HCQ. Retrospective 416 elderly patients in Spain show
11/9	Negative	LateSelf et al., Jdeath, \downarrow 7.0Effect of Hydroxychloroquine onEarly terminated very late stage (65% on supplemental oxygen) RCT with 242 H
11/9	Inconc.	LateBrown et al., Annals of the AmHydroxychloroquine vs. AzithromSmall early terminated very late stage (86% on oxygen, 44% enrolled in the ICU)
11/9	Positive	Late Núñez-Gil et death, ↓7.9 Mortality risk assessment in Spai

Retrospective database study of 1,021 patients in Ecuador, Germany, Italy, and ...

11/6	Positive	PrEPMathai et al.,cases, ↓89Hydroxychloroquine as pre-expos90% reduction in cases with HCQ pre-exposure prophylaxis. Retrospective 604
11/6	Positive	 PEP <i>Dhibar</i> et al., cases, 141 Post Exposure Prophylaxis with H 41% reduction in cases with HCQ PEP. Prospective open label trial with 132 HC
11/4	Positive	Early Cadegiani et death , 182.8 Early COVID-19 Therapy with Azit Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness
11/3	Positive	PrEP Behera et al cases, 127 Role of ivermectin in the preventi Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 he
11/2	Positive	LateLópez et al., Annals of PediatriTelemedicine follow-ups for COVIRetrospective 72 pediatric patients showing HCQ associated with a shorter dur
10/31	Positive	Early Fonseca et hosp., 164.0 Risk of Hospitalization for Covid-1 64% lower hospitalization with HCQ. Retrospective 717 patients in Brazil with ea
10/30	Positive	Late Tehrani et al death , 13.4 Risk factors for mortality in adult Retrospective 255 hospitalized patients, 65 treated with HCQ, showing unadjust
10/27	Positive	PrEP Arleo et al., death , 150.0 Clinical Course and Outcomes of Retrospective hospitalized rheumatic disease patients showing 50% lower mort
10/27	Negative	Late Choi et al., I viral-time , ↑ Comparison of antiviral effect for Health insurance database analysis failing to adjust for disease severity and not
10/26	Positive	Late <i>Frontera</i> et a death, J37.0 Treatment with Zinc is Associate Retrospective 3,473 hospitalized patients showing lower mortality with HCQ+zi
10/26	Positive	EarlyDerwand etdeath, ↓79.4COVID-19 Outpatients - Early Ris79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z (~
10/24	Negative	PEPBarnabas et al., IDWeek (PrepriHydroxychloroquine for Post-expEarly terminated PEP RCT comparing HCQ and vitamin C with 781 patients (83
10/24	Positive	PrEP Goenka et al IgG+, ↓87.2 Seroprevalence of COVID-19 Amo Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding
10/23	Positive	Late Coll et al., A death, ↓45.6 Covid-19 in transplant recipients: Retrospective 652 transplant recipient patients in Spain showing 46% lower mo

10/21	Inconc.	Late Lano et al., death, \downarrow 33.1 Risk factors for severity of COVID 33% lower mortality with HCQ+AZ, p =0.28. Retrospective 122 French dialysis p
10/21	Inconc.	LateDubee et al.,death, ↓46.0A placebo-controlled double blindSmall early terminated late stage (60% on oxygen) RCT in France showing 46% l
10/21	Positive	Late <i>Ñamendys-S</i> death, J32.3 Outcomes of patients with COVID Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HC
10/20	Meta	Early, IHU Marseille (Preprint) (meta Meta-analysis on chloroquine deri Updated meta analysis of 41 studies showing CQ/HCQ OR 0.57, p<0.0001 fro
10/20	Negative	LateSolh et al.,death, ↑18.0Clinical course and outcome of CRetrospective database analysis of 7,816 Veterans Affairs hospitalized patients
10/17	Safety	Early Mohana et al., International Jo Hydroxychloroquine Safety Outco Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderat
10/15	Positive	LateGuisado-Vadeath, ↓20.3Clinical characteristics and outcoRetrospective 607 patients reporting results for early outpatient HCQ use with
10/15	Negative	Late SOLIDARITY death, ↑19.0 Repurposed antiviral drugs for CO WHO SOLIDARITY open-label trial with 954 very late stage (64% on oxygen/vent
10/12	Inconc.	Late Annie et al., death, ↓4.3 Hydroxychloroquine in hospitalize Retrospective database analysis with PSM not including COVID-19 severity, findi
10/11	Inconc.	LateSili et al., medRxiv, doi:10.1101Factors associated with progressAnalysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of
10/8	Positive	Late Aparisi et al death , ↓63.0 Low-density lipoprotein cholester Retrospective 654 hospitalized patients focused on low-density lipoprotein chol
10/8	Negative	Late Soto-Becerr death, ↑84.0 Real-World Effectiveness of hydro Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 200
10/6	Inconc.	Late DISCOVERY death , ↓31.1 DISCOVERY Trial Preliminary Res Early terminated DISCOVERY trial shows improvements in mortality and day 29
10/5	Meta	Early, Prodromos et al., New Microb Hydroxychloroquine is effective, a Meta analysis of 43 studies: "HCQ was found consistently effective against COV
10/2	Positive	Late Nachega et death, 127.6 Clinical Characteristics and Outco

Retrospective 766 hospitalized patients in DRC showing mortality reduced from...

10/1	Positive	Late Almazrou et ventilation, Comparing the impact of Hydroxy Retrospective 161 hospitalized patients in Saudi Arabia showing lower ventilatio
10/1	Meta	PrEP, Garcia-Albe cases, 122 Brief communication: A meta-anal Combination of the four underpowered prophylaxis RCTs to date showing statis
9/30	Positive	PEP Polat et al., cases , 57 Hydroxychloroquine Use on Healt Small prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk
9/30	Positive	LateAyerbe et al.,death, ↓52.2The association of treatment with2075 hospital patients in Spain showing HCQ reduces mortality 52%, odds ratio
9/30	Meta	PrEP, <i>Ladapo</i> et al cases/deat Randomized Controlled Trials of Meta analysis of prophylactic and early treatment RCTs, 24% reduction in cases
9/30	Inconc.	PrEP Abella et al., cases , 15.0 Efficacy and Safety of Hydroxychl Very small early-terminated underpowered PrEP RCT with 64/61 HCQ/control p
9/29	Positive	Late Lammers et death/ICU, \downarrow Observational study 1,064 hospitalized patients in the Netherlands, 53% reduce
9/29	Inconc.	LateDabbous et al., Research SquaA Randomized Controlled StudySmall RCT comparing HCQ and favipiravir, with 50 patients in each arm, finding t
9/28	Meta	PEPLuco, J., ResearchGate, doi:10Hydroxychloroquine as Post-ExpoReanalysis of Boulware et al. PEP trial data showing statistically significant impr
9/27	Meta	PEP Wiseman et cases, 165 Treatment and prevention of early Analysis of Boulware et al. data showing 65% reduction in cases for treatment
9/24	Safety	Early, <i>Gasperetti</i> et al., <i>EP Europace</i> , Arrhythmic safety of hydroxychlor Safety study of 649 patients finding that HCQ administration is safe for short-te
9/24	Positive	Late Shoaibi et al death , 15.4 Comparative Effectiveness of Fa Retrospective database analysis focused on Famotidine but also showing resul
9/23	Negative	Late Ulrich et al., death , ↑6.0 Treating Covid-19 With Hydroxych Small RCT on very late stage use of HCQ, with 48% on oxygen at baseline. 67 H
9/22	Positive	Late Serrano et al death, ↓43.0 COVID-19 and lung cancer: What Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, s

9/21	Inconc.	PrEP <i>Gentry et al.,</i> death, ↓86.7 Long-term hydroxychloroquine us Retrospective patients with rheumatologic conditions showing zero mortality wi
9/21	Inconc.	PrEPRajasinghacases, $\downarrow 27$ Hydroxychloroquine as pre-exposPrEP RCT showing HR 0.73, $p = 0.12$. Trial halted after 47% enrollment, $p < 0.05$
9/21	Inconc.	PrEP Grau-Pujol e cases , 10 Pre-exposure prophylaxis with hy Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. No de
9/21	Safety	EarlyLofgren et al., medRxiv, doi:10Safety of Hydroxychloroquine amAnalysis of 2,795 outpatients not showing significant safety concerns with HCQ
9/18	Meta	LateAxfors et al., medRxiv, doi:10.1Mortality outcomes with hydroxycMeta analysis assigning 87% weight to the RECOVERY trial, producing the same
9/16	Dosing	N/A <i>Karatza</i> et al., Xenobiotica (Pee Optimization of hydroxychloroqui Analysis of HCQ dosing, suggesting that high initial doses followed by low and
9/15	Positive	Late Ashinyo et a hosp. time, Clinical characteristics, treatment Retrospective 307 hospital patients in Ghana showing 33% reduction in hospital
9/14	Positive	LateLauriola et adeath, ↓73.5Effect of combination therapy ofRetrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted h
9/13	Positive	Early Sulaiman et death , ↓63.7 The Effect of Early Hydroxychloro Observational prospective 5,541 patients, adjusted HCQ mortality odds ratio O
9/12	Positive	Late <i>Heberto et a</i> death, ↓53.6 Implications of myocardial injury i Observational prospective 254 hospitalized patients, HCQ+AZ mortality odds ra
9/9	Positive	Late Alamdari et death, ↓55.0 Mortality Risk Factors among Ho Retrospective 459 patients in Iran 93% using HCQ, showing HCQ mortality RR 0
9/9	Inconc.	Early, <i>Kirenga et al</i> recov. time, Characteristics and outcomes of Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% fast
9/9	Negative	PrEP Rentsch et a death, ↑3.0 Effect of pre-exposure use of hyd Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE p
9/9	Inconc.	PrEP Laplana et al cases, ↑56 Lack of protective effect of chloro Survey of 319 autoimmune disease patients taking CQ/HCQ with 5.3% COVID-1
9/7	Review	Revie IHU, Expert Review of Clinical I Natural history and therapeutic op

Review of the current state of knowledge regarding the natural history of and th...

9/5	Positive	LateSynolaki etdeath, ↓23.6The Activin/Follistatin-axis is seveRetrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients
9/4	Inconc.	LateFurtado et al., The Lancet, doi:Azithromycin in addition to standSmall RCT comparing the addition of AZ for very late stage patients on ventilati
9/2	In Vitro	In Vit Wang et al., Phytomedicine, doi Chloroquine and hydroxychloroqu In Vitro study providing novel insights into the molecular mechanism of CQ/HC
9/2	Positive	Early <i>Heras</i> et al., death , ↓92.1 COVID-19 mortality risk factors in Retrospective 100 elderly nursing home patients, HCQ+AZ mortality 11.4% vs
9/2	Inconc.	PrEP de la Iglesia hosp., ↑50.0 Hydroxicloroquine for pre-exposur Analysis of autoimmune disease patients on HCQ, compared to a control group
9/1	Review	Revie <i>Hecel</i> et al., <i>Pharmaceuticals</i> , Zinc(II)—The Overlooked Éminenc Review of zinc as an inhibitor of SARS-CoV-2's RNA-dependent RNA polymerase
9/1	Positive	Early <i>Elbazidi et al., New Microbes a</i> Pandemic and social changes, po Analysis of US states and countries. Country analysis shows a significant correl
8/29	Inconc.	LateCastillo et al., Journal of SteroiEffect of calcifediol treatment anRCT on calcifediol (25-hydroxyvitamin D) treatment for hospitalized COVID-19 p
8/28	Inconc.	LateFried et al.,death, ↑27.0Patient Characteristics and OutcoDatabase analysis of 11,721 hospitalized patients, 4,232 on HCQ. Strong evide
8/27	Positive	PrEP <i>Ferri at al., C</i> cases, ↓63 COVID-19 and rheumatic autoim Analysis of 1641 systemic autoimmune disease patients showing csDMARD (H
8/26	Meta	LateFiolet et al., Clinical MicrobioloEffect of hydroxychloroquine withMeta analysis of late stage studies (and one early treatment study with only 2 d
8/25	Positive	Early <i>Ip</i> et al., med hosp. , ↓45.9 Hydroxychloroquine in the treatm Retrospective 1,274 outpatients, 47% reduction in hospitalization with HCQ with
8/25	Positive	Late Di Castelnu death, J30.0 Use of hydroxychloroquine in hos Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HCQ
8/24	Positive	Late Catteau et al death , ↓32.0 Low-dose Hydroxychloroquine Th Retrospective 8,075 hospitalized patients, 4,542 low-dose HCQ, 3,533 control

8/21	Positive	Early Ly et al., Inte death, \downarrow 55.6 Pattern of SARS-CoV-2 infection a Retrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0
8/21	Safety	N/A <i>Lane</i> et al., The Lancet Rheum Risk of hydroxychloroquine alone Retrospective study of RA patients using HCQ vs. sulfasalazine (another DMAR
8/21	Positive	Late Gonzalez et death , ↓26.6 The Prognostic Value of Eosinop Retrospective study focused on eosinophil recovery with 9,644 hospitalized pat
8/20	Positive	Late Dubernet et ICU, 187.6%, A comprehensive strategy for the Retrospective analysis of 36 hospitalized patients showing HCQ/AZ associated
8/20	Safety	Early Prodromos , C., New Microbes Hydroxychloroquine is protective Review concluding that HCQ/AZ does not cause Torsade de Pointes or related
8/18	Positive	Late Pinato et al., death , 159.0 Clinical portrait of the SARS-CoV Restrospective 890 cancer patients with COVID-19, adjusted mortality HR for H
8/15	Negative	LatePeters et al.,death, ↑9.0Outcomes of Persons With COVIRetrospective study of HCQ use in 9 hospitals in the Netherlands, showing no si
8/14	Inconc.	Late Abd-Elsalam death, ↑20.0 Hydroxychloroquine in the Treatm Small RCT in Egypt with 97/97 HCQ/control patients, showing 58% more recov
8/13	Negative	Late Roomi et al., death, ↑37.7 Efficacy of hydroxychloroquine an Retrospective 176 hospitalized patients (144 HCQ, 32 control) showing no signi
8/11	Safety	Early Bakhshaliyev et al., J. Electroc The effect of 5-day course of hyd Safety study of 109 patients showing 5 days of HCQ+AZ did not lead to clinicall
8/11	Negative	Late Saleemi et a viral- time, ↑ Time to negative PCR from symp Retrospective 65 HCQ+AZ, 20 control patients, showing median time to negativ
8/8	Inconc.	LateLopez et al., Int. J. AntimicrobEffects of Hydroxychloroquine onSmall retrospective study of 29 ICU patients comparing those with HCQ plasma
8/6	Review	Revie <i>McCullough</i> et al., <i>The Americ</i> Pathophysiological Basis and Rat Review of pathophysiological principles related to early outpatient treatment an
8/6	Meta	PEP, Watanabe et al., Open Letter (L Concerns regarding the misinterp Open letter signed by 38 professors and doctors regarding misinterpretation of
8/5	Negative	PrEP Singer et al., cases, †9.0 Hydroxychloroquine ineffective fo

Comparison of the percentage of SLE/RA patients on immunosuppressants tha...

8/4	Inconc.	Late <i>Kamran</i> et al progression Clearing the fog: Is HCQ effective Study of 349 low-risk hospitalized patients with 151 non-consenting or ineligible
8/3	Positive	LateBerenguer etdeath, ↓61.9Characteristics and predictors ofRetrospective 4035 hospitalized patients in Spain showing reduced mortality wi
8/3	Positive	LateYu et al., Science China Life ScBeneficial effects exerted by hydrRetrospective 2,882 patients in China, median age 62, 278 receiving HCQ, medi
8/2	Positive	Late Davido et al., int./hosp., ↓ Impact of medical care including Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly re
8/2	In Vitro	In Vit Sheaff , R., bioRxiv, doi:10.1101 A New Model of SARS-CoV-2 Infe In vitro study presenting a new theory on SARS-CoV-2 infection and why HCQ/C
7/29	Positive	LateD'Arminio Mdeath, \downarrow 34.0Effectiveness of HydroxychloroquHCQ+AZ adjusted death HR 0.44, p =0.009. Propensity scores include baseline
7/28	Inconc.	Late BaŞaran et al., Turk. J. Med. ScOutcome of Non-Critical COVID-1Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23
7/26	Inconc.	PEP <i>Mitjà</i> et al., death , J32.0 A Cluster-Randomized Trial of Hy Death rate reduced from 0.6% to 0.4%, RR 0.68, not statistically significant due
7/24	Positive	PrEP <i>Khurana</i> et a cases, <i>151</i> Prevalence and clinical correlates Study of hospital health care workers showing HCQ prophylaxis reduces COVID
7/23	Negative	LateCavalcanti edeath, 16.0Hydroxychloroquine with or withoLate stage RCT of 667 hospitalized patients with up to 14 days of symptoms at
7/22	In Vitro	In Vit <i>Hoffmann</i> et al., <i>Nature</i> , (2020 Chloroquine does not inhibit infec The title of this paper does not appear to match the results. Fig. 1b @100uM s
7/22	Negative	Late <i>Rivera</i> et al., death , ↑2.4 Utilization of COVID-19 Treatment Retrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ
7/22	Negative	Late <i>Kelly et al., B</i> death, ↑143 Clinical outcomes and adverse ev Retrospective 82 hospitalized patients HCQ/AZ, 52 SOC, not finding statistically
7/21	Positive	Late Bernaola et death , ↓ 17.0 Observational Study of the Efficie HCQ HR 0.83 [0.77-0.89] based on propensity score matched retrospective ana

7/20	Inconc.	PrEP Desbois et al., Research SquarPrevalence and clinical features oRetrospective 199 sarcoidosis patients showing RR 0.83, $p=1.0$.
7/20	Meta	Early <i>Risch</i> , <i>H.</i> , <i>American Journal of</i> Response to: "Early Outpatient Tr Updated meta analysis including 7 new studies of high-risk outpatients, for a tot
7/18	Meta	PEP <i>Watanabe</i> , <i>M., arXiv.org, arXiv:2</i> Efficacy of Hydroxychloroquine a Secondary analysis of Boulware et al.'s PEP trial and treatment delay-response
7/19	Inconc.	Late McGrail et al death, ↑70.0 COVID-19 Case Series at UnityPoi HCQ+AZ early in the epidemic had a fairly good success rate with few complica
7/17	Inconc.	Late <i>Lyngbakken</i> death, 13.7 A pragmatic randomized controll Small RCT of nasopharyngeal viral load not showing significant differences. The
7/16	Positive	Early Hong et al., I viral+, 164.9 Early Hydroxychloroquine Admini HCQ 1-4 days from diagnosis was the only protective factor against prolonged
7/16	Inconc.	Early <i>Skipper</i> et al no recov., ↓ Hydroxychloroquine in Nonhospit ~70 to 140 hour (inc. shipping) delayed outpatient treatment with HCQ reduced
7/16	Inconc.	Early <i>Mitjà</i> et al., hosp., 125.0 Hydroxychloroquine for Early Trea This paper has inconsistent data - some of the values reported in Table 2 and t
7/15	Negative	LateGupta et al.,death, ↑6.0Factors Associated With Death inAnalysis of 2215 intensive care unit patients showing no significant differences
7/14	Inconc.	Late Trullàs et al., death , ↓35.6 High in-hospital mortality due to Retrospective 100 hospitalized patients in Spain showing lower mortality with H
7/14	Inconc.	Early Chowdhury et al., Research Sq A Randomized Trial of Ivermectin Small 116 patient RCT comparing Ivermectin-Doxycycline and HCQ+AZ, not sho
7/11	Negative	Late <i>Lecronier</i> et death , ↓ 42.0 Comparison of hydroxychloroquin Retrospective 80 ICU patients, 22 SOC, 20 lopinavir/ritonavir, 38 HCQ. 28 day m
7/10	Negative	Late Cravedi et al death, ↑53.0 COVID-19 and kidney transplanta Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality
7/10	Inconc.	LateChen et al.,viral+, ↓24.0A Multicenter, randomized, open-l2 very small studies with hospitalized patients in Taiwan. RCT with 21 treatment
7/9	Meta	Early, Raoult et al., Preprint (Preprint) Hydroxychloroquine and Azithrom

Updated meta analysis showing significant reductions in mortality and viral she...

7/8	Review	N/A <i>Li</i> et al., <i>Cell Death & Disease v</i> Is hydroxychloroquine beneficial f Review of the anti-inflammatory, antiviral, and protective vascular effects of CQ
7/7	Review	RevieGoldstein, L., Preprint, July 7, 2Hydroxychloroquine-based COVID85% of globally surveyed physicians recognized HCQ as at least partially effecti
7/7	Negative	LateAn et al., meviral+, ↓3.0Treatment Response to HydroxycRetrospective of hospitalized patients with 31 HCQ patients and 195 standard t
7/3	Positive	PrEP Zhong et al., cases, 191 COVID-19 in patients with rheuma Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on
7/1	Positive	LateArshad et aldeath, ↓51.3Treatment with HydroxychloroquiHCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Prop
7/1	Safety	N/A Samuel et al., Heart Rhythm, d Incidence of arrhythmias and elec In pediatric patients with PCR positive active COVID-19 infection, significant arrh
6/30	Positive	Late Martinez-Lo death, ↓33.0 Multiple Myeloma and SARS-CoV Retrospective 167 multiple myeloma patients in Spain
6/30	Positive	Late Mikami et al death , ↓ 47.0 Risk Factors for Mortality in Patie HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not s
6/30	Negative	Late <i>Komissarov</i> viral load, ↑ Hydroxychloroquine has no effect Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12
6/29	Positive	PrEP Ferreira et al cases, \downarrow 47 Chronic treatment with hydroxych Chronic treatment with HCQ provides protection against COVID, odds ratio 0.51
6/29	Safety	N/AMfeukeu-Kuate et al. (Preprint)Electrocardiographic safety of daiNo life-threatening modifications of the QT interval was observed in non-severe
6/25	Inconc.	PrEP Gendebien e cases , \downarrow 3.9 Systematic analysis of COVID-19 Small study of 152 SLE patients taking HCQ with a phone survey for COVID-19
6/25	Positive	Early Lagier et al., death, ↓59.0 Outcomes of 3,737 COVID-19 pat Early treatment leads to significantly better clinical outcome and faster viral loa
6/23	Positive	Late Bousquet et death , 142.8 ADL-dependency, D-Dimers, LDH Observational prospective 108 hospitalized patients 65 and older, showing HC

6/22	Positive	Late Fontana et a death , ↓ 50.0 SARS-CoV-2 infection in dialysis p Very small observational study of 15 dialysis patients showing HCQ mortality R
6/22	Positive	Early Chen et al., viral- time, ↓ Efficacy and safety of chloroquin Significantly faster clinical recovery and shorter time to RNA negative (from 7.0
6/21	Inconc.	LateFaíco-Filhoviral rate, ↓8No benefit of hydroxychloroquineViral load comparison for 34 HCQ and 32 control patients hospitalized with mo
6/19	Positive (news)	PrEPSMSH Sawai Man Singh HospiHCQ beneficial as preventive drugPrEP with 4,300 very high risk healthcare workers in a hospital with up to 500+
6/19	Negative (news)	LateNIH, study not available yet (NNIH halts clinical trial of hydroxycNIH halts late stage trial reporting no harm and no benefit. 470 patients.
6/19	Positive	Late Sbidian et al death , ↑5.0. Hydroxychloroquine with or witho Retrospective of 4,642 hospitalized patients in France showing significantly fast
6/19	Animal	N/AKapstein et al., bioRxiv, doi:10Favipiravir at high doses has poteAnimal study with Syrian hamsters, showing treatment of SARS-CoV-2-infected
6/18	Inconc.	Late Paccoud et death, ↓11.0 Compassionate use of hydroxych Retrospective of 89 hospitalized patients, survival HR 0.89 [0.23-3.47], not stati
6/17	Positive	LateXue et al., J. Med. Virology, JunHydroxychloroquine treatment in30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in pr
6/17	Inconc.	Late <i>Luo et al., A</i> death, ↑2.2 COVID-19 in patients with lung ca Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortalit
6/16	Inconc.	LateKim et al., Korean J Intern MedLopinavir-ritonavir versus hydroxySmall retrospective study of hospitalized patients with 31 lopinavir-ritonavir and
6/16	Positive (news)	PrEPWHIP COVID-19 (News) (not inHenry Ford Health System still mOngoing WHIP COVID-19 HCQ PrEP study reports analyzing their data and seei
6/16	Positive	PrEP Huang et al., hosp., ↓80.0 Clinical characteristics of 17 patie Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.61% wit
6/12	Theory	Theo <i>Scherrmann, AAPS J 22, 86 (2</i> Intracellular ABCB1 as a Possible Theory paper, not included in the study count or percentages. Proposes a new
6/12	Negative	Late <i>Giacomelli</i> et al., Journal of M Early administration of lopinavir/ri

Late stage study of hospitalized patients comparing treatment starting within 5 \ldots

6/10	Inconc.	LateWang et al.,death, 15.8Comorbidity and SociodemograpDatabase analysis of 7,592 patients in NYC, showing adjusted HCQ mortality od
6/10	Positive	Early Otea et al., medRxiv, doi:10.110 A short therapeutic regimen base 80 moderate cases, HCQ+AZ appears to reduce serious complications and dea
6/9	Positive	 Early <i>Pirnay</i> et al., Hosp. Pharm. and Beneficial effect of Hydroxychloro 68 very high risk nursing home residents, median age 86, HCQ+AZ early treatm
6/9	Positive	PrEP Bhattachary cases , ↓80 Pre exposure Hydroxychloroquine HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
6/6	Review	Revie Roussel et al., New Microbes a Influence of conflicts of interest o Shows a correlation (Spearman test, $p = 0.017$) between the amount received fr
6/6	Meta	Early, <i>Million et al., New Microbes an</i> Clinical Efficacy of Chloroquine de [H]CQ effective and reduces mortality by a factor 3. Meta analysis of 20 studies.
6/5	Negative	Late RECOVERY death , ↑9.0 Effect of Hydroxychloroquine in H RECOVERY trial finds no significant benefit for very late stage very sick patients
6/3	Positive (see notes)	PEPBoulware etcases, 17A Randomized Trial of HydroxychlCOVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within
6/1	Dosing	N/A <i>Al-Kofahi</i> et al., <i>Clin. Pharmaco</i> Finding the Dose for Hydroxychlo Analysis of HCQ dosing regimens, recommending: PrEP: 800mg loading dose f
5/31	Positive	Early Guérin et al., death , \downarrow 43.0 Azithromycin and Hydroxychloroq Mean clinical recovery time reduced from 26 days (SOC) to 9 days, <i>p</i> <0.0001 (
5/28	Positive	LateChamieh et al., medRxiv 2020Viral Dynamics Matter in COVID-1HCQ+AZ potentially explains 94.7% success in treating a fairly complex cohort.
5/28	Positive	PrEPChatterjee etcases, ↓66Healthcare workers & SARS-CoV4+ doses of HCQ associated with a significant decline in the odds of getting inf
5/28	Positive	Late <i>Huang</i> et al., viral- time, ↓ Preliminary evidence from a multi 197 CQ patients, 176 control. Mean time to undetectable viral RNA and duration
5/27	Inconc.	LateGoldman etdeath, 122.3Remdesivir for 5 or 10 Days in PaStudy focused on remdesivir but with results for HCQ in the supplementary app

5/28	Negative	Late <i>Kuderer et al</i> death, ↑134 Clinical impact of COVID-19 on pa Retrospective 928 cancer patients, showing HCQ OR 1.06 [0.51-2.20]. HCQ+AZ
5/28	Inconc.	PrEP Gianfrances hosp., J3.3 Characteristics associated with h Analysis of rheumatic disease patients showing no significant association betw
5/27	Meta	Early Risch , American Journal of Epi Early Outpatient Treatment of Sy Five studies, including two controlled clinical trials, have demonstrated significa
5/25	Negative	LateIp et al., meddeath, ↓1.0Hydroxychloroquine and TocilizuRetrospective study of late stage use on 2,512 hospitalized patients showing n
5/22	Positive (advisory)	PEP, <i>ICMR</i> , <i>Indian Council of Medic</i> Revised advisory on the use of H Healthcare workers on HCQ prophylaxis less likely to get COVID. Significant dos
5/22	Retracted	LateMehra et al., The Lancet, MayHydroxychloroquine or chloroquinIncorrect at first read (implausible death, ventilation, and population numbers)
5/19	Negative	LateSingh et al.,death, ↓5.0Outcomes of HydroxychloroquineEHR analysis of 3,372 hospitalized COVID-19 patients not showing a significant
5/18	Positive	LateKim et al., mhosp. time,Treatment Response to HydroxycRetrospective of 97 moderate cases. Time to viral clearance significantly shorte
5/18	Positive	EarlyAhmad et al., doi:10.1101/2020Doxycycline and Hydroxychloroqu54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22
5/16	Inconc.	PrEP Macias et al hosp., ↓25.5 Similar incidence of Coronavirus Very small retrospective study of rheumatic disease patients, sample size is to
5/15	Positive	Late Yu et al., Sci death, ↓60.5 Low Dose of Hydroxychloroquine Retrospective, 550 critically ill patients. 19% fatality for HCQ versus 47% for non
5/14	Negative	Late Mahévas et death, ↑20.0 Clinical efficacy of hydroxychloro Observational study of 181 patients with advanced disease requiring oxygen sh
5/13	Positive	LateOkour et al., Journal of PharmaHydroxychloroquine and azithromOdds of PCR-positive decrease by 53% for each unit increase in HCQ log-conce
5/12	Inconc.	PrEP Cassione et cases, ↑49 COVID-19 infection in a northern-It Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 a
5/11	Inconc.	Late Shabrawishi viral+, 14.7 Negative nasopharyngeal SARS-C

Retrospective 93 hospitalized patients in Saudi Arabia showing a non-statisticall...

5/11	Negative	Late Rosenberg e death, ↑35.0 Association of Treatment With Hy Restrospective observational late stage study showing no significant difference
5/10	Positive	LateAlberici et aldeath, ↓42.9A report from the Brescia Renal CAnalysis of 94 hemodialysis COVID-19 positive patients. Reduction in death see
5/8	Ex Vivo	Ex Vi <i>Grassin-Delyle</i> et al., <i>Clinical In</i> Chloroquine Inhibits the Release On human lung parenchymal explants, CQ concentration clinically achievable in t
5/8	Positive	LateCarlucci et al., J. Med. MicrobiZinc sulfate in combination with aRetrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / tra
5/7	Inconc.	PrEPKonig et al.,hosp., 13.0Baseline use of hydroxychloroquiAnalysis of 80 SLE patients diagnosed with COVID-19, showing the frequency o
5/7	Theory	Theo <i>Derendorf, H., Int. J. Antimicro</i> Excessive lysosomal ion-trapping Discusses pharmacokinetic properties of HCQ+AZ as a potential underlying me
5/7	Inconc.	Late Geleris et al int./death, ↑ Observational Study of Hydroxych There appears to be a major error in this paper. Before propensity matching, 38
5/7	Positive (news)	N/ASermo (News) (not included inSermo reports: COVID-19 treatmeHCQ used by 55% of physicians worldwide for COVID. Survey of 6,150 physicia
5/6	Animal	N/A <i>Maisonnasse et al., Nature, 20</i> Hydroxychloroquine use against Monkey study which reports no effect of HCQ or HCQ+AZ. However, there are s
5/5	Positive	LateMembrillo ddeath, ↓55.1Early Hydroxychloroquine Is Asso166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 times
5/5	Positive	Early, <i>Million</i> et al., <i>Travel Med Infect</i> Early Treatment of COVID-19 Pati Retrospective 1061 patients. HCQ+AZ safe and results in a low fatality rate.
5/5	Inconc.	PrEP Gendelman cases , 18.1 Continuous Hydroxychloroquine o Very small study of rheumatic disease/autoimmune disorder patients showing
5/5	Positive	PrEP Mitchell et a death , ↓99.0 Markedly Lower Rates of Coronav Analysis of COVID-19 amongst 2.4B people shows a wide counterintuitive disp
5/4	Inconc.	PrEP Huh et al., m cases, ↑47 Association of previous medicati Database analysis of many drugs and COVID-19 cases, with 23 cases taking H

5/1	Safety	N/A <i>Mercuro</i> et al., JAMA Cardiol., Risk of QT Interval Prolongation A Study of 90 hospitalized patients given HCQ, 53 also receiving AZ, 53% hyperte
5/1	Safety	N/A Bessière et al., JAMA Cardiol., Assessment of QT Intervals in a Study of 40 very serious condition ICU patients, 75% required invasive mechani
5/2	Positive (news)	LateSeydi (News) (not included in tCoronavirus: a study in Senegal cPreliminary results of Senegal trial with 181 patients showing faster recovery wit
4/30	Positive	Early Meo et al., Eur. Rev. Med. Phar Efficacy of chloroquine and hydro Analysis of COVID-19 and malaria, finding that COVID-19 is highly pandemic in c
4/27	Positive	Late Sánchez-Álv death, ↓45.9 Status of SARS-CoV-2 infection in Analysis of 868 patients on renal replacement therapy. Statistically significant re
4/29	Safety	N/ASaleh et al., Circulation: ArrhytThe Effect of Chloroquine, Hydrox201 hospitalized patients. No serious side effects of HCQ. No instances of Tors
4/25	In Vitro	In Vit Andreani et al., Microbial Patho In vitro testing of combined hydro HCQ and AZ has a synergistic effect <i>in vitro</i> on SARS-CoV-2 at concentrations c
4/24	Inconc.	Early Ashraf et al., death , ↓67.5 COVID-19 in Iran, a comprehensiv Small limited trial with 100 patients concluding that HCQ improved clinical outc
4/21	Positive	Early <i>Izoulet M., S</i> death, ↓85.0 Countries which Primarily Use Ant Compares the dynamics of daily deaths in the 10 days following the 3rd death i
4/21	Negative	Late Magagnoli e death, ↑31.0 Outcomes of hydroxychloroquine Retrospective 368 hospitalized patients, no statistically significant reduction in
4/17	Positive	PEPLee at al., Int. J. Antimicrob. AgCan Post-Exposure Prophylaxis fPost exposure prophylaxis of 211 high-risk people after major exposure event i
4/16	Negative	LateBorba et al., JAMA Network OChloroquine diphosphate in two dComparison of typical CQ dosage with high dosage CQ (600mg CQ twice daily
4/15	Positive	Early, <i>Esper</i> et al., hosp., ↓64.0 Empirical treatment with hydroxy 636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 days (6
4/15	Theory	Theo Brufsky , A., J. Medical Virology, Hyperglycemia, hydroxychloroqui Theory on the effectiveness of HCQ. HCQ has been shown to block the polariza
4/14	Negative	Late Tang et al., B viral+, 121.5 Hydroxychloroquine in patients wi

150 patients very late stage RCT showing no significant difference. Treatment v...

4/13	Review	LateGao et al., Biosci Trends, MayUpdate on Use of Chloroquine/HyIncreasing evidence from completed clinical studies shows CQ and HCQ effecti
4/12	Negative	Late Barbosa et a death, ↑147 Clinical outcomes of hydroxychlor Small retrospective study with 63 patients (32 treated with HCQ), showing no ef
4/11	Positive	Early Gautret et al., Travel Medicine Clinical and microbiological effect Pilot study suggesting improvement with HCQ+AZ and recommending further s
4/10	Meta	LateLover, medRxiv, doi:10.1101/20Quantifying treatment effects of hSecondary analysis of Gautret et al. showing "modest to no impact of HCQ treat
4/3	Theory	Theo <i>Fantini</i> et al., Int J Antimicrob Structural and molecular modellin In-silico analysis confirming the antiviral properties of CQ, showing a new mech
4/1	Positive	Early Huang et al., no recov., ↓ Treating COVID-19 with Chloroqui 22 patients. All CQ patients discharged by day 14 versus 50% of Lopinavir/Roti
3/31	Positive	LateChen et al.,pneumonia,Efficacy of hydroxychloroquine in62 patients. RCT showing significantly faster recovery with HCQ. 13% progress
3/31	In Vitro	In Vit <i>Clementi</i> et al., Front. Microbiol Combined Prophylactic and Ther In vitro study, not included in the study count or percentages, showing greater in
3/28	Negative	LateMolina et al., Médecine et MalNo evidence of rapid antiviral clea11 patients with severe cases. No evidence of benefit for HCQ. Binary PCR eval
3/26	Positive	Late Zhong Nans viral+, ↓80.0 Efficacy and safety of chloroquin 197 patients. CQ effective. Day 10 viral RNA negative 91.4% HCQ versus 57.4%
3/24	Theory	TheoPagliano et al., Clin. Infect. DisIs Hydroxychloroquine a PossibleCQ and HCQ inhibit replication at early stages of infection, no similar effect repo
3/23	Theory	Theo Hu et al., Nature Nanotechnolo Insights from nanomedicine into CQ is known in nanomedicine research for the investigation of nanoparticle upta
3/21	Positive (advisory)	PrEPICMR, Indian Council of MedicAdvisory on the use of hydroxy-chRecommends HCQ for prophylaxis in asymptomatic healthcare workers as foun
3/20	Positive (news)	LateHu et al., Shanghai CombinedShanghai Experience of COVID-19Clinical studies of HCQ with 184 cases and 21 hospitals show HCQ is effective.

3/18	In Vitro	In Vit Liu et al., Cell Discovery 6, 16 (Hydroxychloroquine, a less toxic
5/10	in vido	HCQ effective in vitro and less toxic than CQ. In addition to direct antiviral activit
3/17	Inconc.	Early Gautret et al viral+, ↓66.0 Hydroxychloroquine and azithrom HCQ was significantly associated with reduction / elimination of viral load, whic
3/17	Review	N/A Sahraei et al., Int. J. Antimicrob Aminoquinolines against coronavi Discussion of mechanisms of action, CQ vs. HCQ, early studies, safety.
3/13	Review	N/A Todaro and Rigano (Review) (P An Effective Treatment for Coron Discussion of existing research, treatment guidelines, and mechanisms of actio
3/12	Theory	Theo Devaux et al., International Jou New insights on the antiviral effec Discusses mechanisms of CQ interference with the SARS-CoV-2 replication cycle.
3/10	Meta	N/A Cortegiani et al., J. Crit. Care, J A Systematic Review on the Effic Review of six articles and 23 ongoing clinical trials in China recommending rese
3/9	In Vitro	N/A Yao et al., Clin. Infect. Dis., 202 In Vitro Antiviral Activity and Proje HCQ is more potent than CQ <i>in vitro</i> for inhibiting SARS-CoV-2. Simulates HCQ c
3/6	Negative	LateChen et al., JprogressionA pilot study of hydroxychloroqui30 moderate hospitalized cases, all recovered. Time to RNA negative compara
3/4	Review	Late Colson et al., Int J. Antimicrob Chloroquine and Hydroxychloroqu Recommending CQ and HCQ for COVID-19 based on 20 clinical studies in Chin
2/20	Positive	LateJiang et al., Chin. J. Tuberc. ReExpert Consensus on ChloroquinEarly trials in China show CQ results in shorter hospital stays and improved pati
2/19	Positive	LateGao et al., BioScience Trends,Breakthrough: Chloroquine phospResults from 15 clinical trials in China showing CQ is effective.
2/17	Positive (news)	LateSun Yanrong, deputy head of tAntimalarial drug confirmed effecHCQ under clinical trials in >10 hospitals in China and has shown fairly good effi
2/11	Positive	Late Xia et al., Ch viral+, \downarrow 37.5 Efficacy of Chloroquine and Lopin Early results from a very small trial, reported within the application for a later tria
2/4	In Vitro	In Vit Wang et al., Cell Res. 30, 269– Remdesivir and chloroquine effec In vitro study, not included in the study count or percentages. Remdesivir and C
2017	Dosing	N/A <i>Chhonker</i> et al., Journal of Chr Simultaneous quantitation of hydr

Presents a method for quantification of HCQ in mouse blood and tissues. They \ldots

2014	Animal	Animal Browning , D., Pharmacology of Pharmacology of Chloroquine an Review of the pharmacology of CQ and HCQ. Some notable points: - HCQ and C
2014	In Vitro	In Vit <i>de Wilde et al., Antimicrobial A</i> Screening of an FDA-Approved C CQ inhibits SARS-CoV, MERS-CoV, and HCoV-229E-GFP replication in the low-mi
2012	Animal	Animal Yan et al., Cell Research, 23, 3 Anti-malaria drug chloroquine is hi CQ, a known autophagy inhibitor that is in clinical use, can efficiently ameliorate
2009	Animal	Animal <i>Keyaerts</i> et al., Antimicrob. Ag Antiviral Activity of Chloroquine a CQ inhibits HCoV-OC43 replication in HRT-18 cells. A lethal HCoV-OC43 infectio
2008	In Vitro	In Vit <i>Kono et al., Antiviral Research,</i> Inhibition of human coronavirus 2 CQ significantly decreased viral replication of HCoV-229E at concentrations low
2006	In Vitro	In Vit Savarino et al., Lancet Infect New insights into the antiviral effe Update to 2003 paper, not included in the study count or percentages. Hypothe
2005	In Vitro	In Vit <i>Vincent</i> et al., Virol. J. 2:69, 200 Chloroquine is a potent inhibitor o In vitro study, SARS-CoV-1, not included in the study count or percentages. CQ h
2004	In Vitro	In Vit <i>Keyaerts</i> et al., Biochem. Bioph In vitro inhibition of severe acute r In vitro study, SARS-CoV-1, not included in the study count or percentages. IC50
2003	Theory	TheoSavarino et al., Lancet InfectEffects of chloroquine on viral infeNot included in the study count or percentages. Discussion/review noting that C
1918	Inconc.	N/A <i>Burrows, E., Medical Record, 9</i> A confirmatory report upon the a Quinine was found to be effective for the Spanish Flu in 1918.
1890	Inconc. (news)	N/A <i>Le Grelot (News) (not included</i> Quinine use for the Russian influe Quinine and antipyrine, a bitherapy for defying death during the Russian influenz
1889	Inconc. (news)	N/A <i>Edwin Wiley Grove</i> (<i>News</i>) (<i>no</i> Laxative Bromo Quinine Quinine has been used for respiratory infections since 1889. Not included in the